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p“A stupid man’s report of what a clever man says is never
accurate because he unconsciously translates what he hears
into something he can understand.”
—Bertrand Russell
“You are smart when you only believe half of what you hear.
You’re wise when you know which half to believe.”
—Anonymous
For this year’s American College of Cardiology (ACC)
eetings, a total of 933 abstracts were reviewed for angiog-
aphy and interventional cardiology; 308 were accepted for
resentation. Last year, the angiography and interventional
ardiology highlights (1) included such varied topics as
istal protection, new thromboatherectomy devices, inflam-
ation, drug-eluting stents (DES), and peripheral interven-
ion. This year, DES and peripheral intervention continued
o be “hot” areas, but added to that was important work on
ur ever-expanding technologic options, such as bone mar-
ow stem-cell injections, valve repair, novel myocardial
nfarction (MI) therapies, new diagnostic modalities, and
ther interventions.
rug-eluting stents. Two late-breaking clinical trials, A
andomized comparison of sirolimus-eluting and an un-
oated stent in the prevention of restenosis in small coronary
rteries (SES-SMART) and Direct Stenting Using the
irolimus-Eluting Bx Velocity Stent (DIRECT), were pre-
ented by Ardissino (2) and Moses (3), respectively. The
ES-SMART trial (2) was a randomized trial comparing
irolimus stents with uncoated stents in people with de novo
esions in small coronary vessels (2.75 mm), and showed a
inary restenosis rate of 9.8% with sirolimus stents versus
3.1% with uncoated stents (p  0.001). Clinical events of
eath (0% vs. 1.6%), MI (1.6% vs. 7.8%), and target lesion
evascularization (7.0% vs. 21.1%) were also dramatically
educed in the sirolimus stent group. The benefits were
resent across multiple subgroups and extended the benefits
een with sirolimus stents in other studies. The DIRECT
tudy (3) was a nonrandomized trial comparing direct
tenting with a sirolimus-coated stent (n  225) in histor-
cal control subjects treated with sirolimus stents, but using
predilation delivery strategy (n  412). The results
howed no significant differences between the direct and
redilated cohorts meeting prespecified criteria for nonin-
eriority for eight-month qualitative coronary angiographic
From St. Luke’s Episcopal Hospital, Texas Heart Institute, Baylor College of
tedicine, University of Texas Health Science Center at Houston, Houston, Texas.QCA) late loss and clinical events, and there was no
ignificant difference in eight-month QCA binary
estenosis.
Other important data on DES were also presented. A
eport by Hermiller et al. (4) highlighted the diabetic subset
n TAXUS, in whom the benefits seen in the overall
opulation were preserved. Pinto et al. (5) presented long-
erm follow-up of the First-in-Man experience and showed
ontinued long-term safety and efficacy up to four years.
arks et al. (6) presented a cost-efficacy analysis of DES, in
hich overall procedural costs were increased, but less than
he cost of the stent itself.
eripheral intervention. In another late-breaking clinical
rial session, Dr. Gray presented the results of the overall
cculink for Revascularization of Carotids in High Risk
atients (ARCHeR) experience with carotid stenting and
istal protection (7). These studies (ARCHeR I to III)
nvolved a variety of techniques, devices, and end points
ARCHeR I without distal protection devices; ARCHeR II
nd III with increasingly sophisticated technology). In the
verall experience, there was a very low incidence of adverse
linical events for stenting with distal protection in patients
therwise at high surgical risk, achieving prespecified non-
nferiority in comparison to surgical carotid endarterectomy
using historical controls). The outcomes appeared durable,
s witnessed by a low incidence of target lesion revascular-
zation at one year.
one marrow stem-cell injections. Three important pre-
entations discussed this exciting new technique. Perin et al.
8) presented their long-term experience with transendocar-
ially injected autologous bone marrow stem cells in 10
atients with ischemic cardiomyopathy. They found no
rrhythmias and a sustained improvement in exercise capac-
ty. Fuchs et al. (9) presented their initial feasibility and
afety experience with transendocardial injection of stem
ells in 27 patients. Tse et al. (10) presented three- and
ix-month follow-up data on 12 patients; there were no
rrhythmias and better perfusion noted on single-photon
mission computed tomography (SPECT) with sestamibi.
alve repair. Dr. Feldman presented data from the Endo-
ascular Valve Edge-to-Edge Repair Study (EVEREST)-1
linical experience with percutaneous mitral valve repair in
nother of the late-breaking clinical trial sessions (11). This
echnique involves an edge-to-edge technique that is a
ercutaneous modification of the single-stitch surgical tech-
ique, which involves a stitch linking the anterior and
osterior leaflets, and significantly reduces mitral regurgita-
ion (MR). The current experience involves 10 patients (of
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ACC 2004 Annual Session Highlights July 21, 2004:13A–15Atotal of 20) undergoing percutaneous placement of a clip
hat is advanced trans-septally. In these 10 patients, MR
as reduced to 2 for up to six months’ follow-up, with
ither improvement or no worsening of New York Heart
ssociation functional class. There was one instance where
he clip detached from one of the leaflets.
Eltchaninoff et al. (12) documented follow-up on the
rench percutaneous aortic valve experience in six patients
ith calcific aortic stenosis who were turned down for
urgery. Of the six procedures, five were successful, with one
eath (related to immediate migration of the prosthesis; two
f the six patients are currently alive).
I: novel therapies. One entire late-breaking clinical trial
ession focused on novel therapies for acute MI. Dr. Stone
resented the results of Enhanced Myocardial Efficacy and
emoval by Aspiration of Liberated Debris (EMERALD)
13), which examined the use of a distal protection device
or primary percutaneous coronary intervention (PCI) in
atients with acute MI. A total of 401 patients were
andomized to receive either PCI alone or PCI with the use
f a Guardwire PLUS (Medtronic, Minneapolis, Minne-
ota) for distal protection. The primary end points were
omplete (70%) ST-segment resolution and infarct size by
echnetium-99m SPECT. There was no significant differ-
nce in either of the primary end points or in the final
orrected Thrombolysis In Myocardial Infarction (TIMI)
rame counts between the groups.
Dr. O’Neill presented the results of the Acute Myocardial
nfarction With Hyperoxemic Therapy (AMIHOT) study
14), an investigation the use of hyperoxemic reperfusion
ith aqueous oxygen during primary PCI. Although the
rocedure was well tolerated, there was no significant
eduction in creatine kinase release and no improvement in
T-segment resolution, although there was a trend toward
etter ST-segment resolution in patients with anterior MI.
inal analyses of infarct size and regional wall motion by
chocardiography will be forthcoming.
The Calderet in ST-Elevation Myocardial Infarction
CASTEMI) study, presented by Dr. Tzivoni (15), involved
87 patients with acute MI who were randomized to
lacebo or one of two doses of caldaret (a drug that
odulates calcium handling by inhibiting calcium entry into
he cell via the Na/Ca2 exchanger, removes intracellular
alcium into the sarcoplasmic reticulum, and decreases
alcium overload during ischemia and/or reperfusion) at
7.5 mg (low dose) or 172.5 mg (high dose). The target
tudy population was 247 of 387 patients with TIMI flow
rade 0/1 on the baseline angiogram. The primary end point
f the study—SPECT infarct size at day 7—was not
ifferent between the groups. There did appear to be
ifferences in the high-dose group in patients with an
nterior infarction
The Ongoing Tirofiban in Myocardial Infarction Evalu-
tion (ON-TIME) trial, presented by Dr. de Boer (16),
xamined the efficacy of facilitated PCI in 457 patients with
cute MI who were randomized to early treatment with fither placebo or a glycoprotein IIb/IIIa antagonist. The
rimary end point was TIMI flow grade on the initial
ngiogram (mean time 59 min, range 11 to 178 min). The
IMI flow grade 3 was not significantly different with
retreatment with a glycoprotein IIb/IIIa antagonist, and
here was no difference in clinical events, although there was
etter TIMI flow grade 2/3.
The Percutaneous Transvenous Transplantation of Au-
ologous Myoblasts in the Treatment of Postinfarction
eart Failure (POZNAN) experience, presented by Dr.
iminiak (17), examined the feasibility and safety of a
ransvenously accessed delivery of skeletal myoblast cells
nto the myocardium in a small number of patients (n 10)
ith acute MI. Nine of the 10 procedures that were
ndertaken were successful. One was abandoned for tech-
ical delivery reasons. There were no arrhythmias. With
hese encouraging preliminary feasibility data in hand,
dditional studies are ongoing.
Finally, the Combined Angioplasty and Pharmacological
ntervention Versus Thrombolytics Alone in Acute Myo-
ardial Infarction (CAPITAL-AMI) trial, presented by
r. Le May (18), looked at 170 MI patients, comparing
retreatment with a fibrinolytic agent and intervention
ersus fibrinolytic therapy alone. The primary end point of
he composite of death, MI, stroke, and recurrent unstable
ngina was significantly lower in the group treated with the
ombination of a fibrinolytic agent and PCI. These results
ere primarily driven by reductions of re-infarction and
efractory unstable ischemia. There was no difference in
ajor bleeding.
ew diagnostic technologies. Yaneza et al. (19) presented
he results of two types of texture analysis of intravascular
ltrasound (IVUS) images, using multifractal techniques
nd wavelet decomposition. They found a significant asso-
iation between plaque morphology and texture analysis
hen using both techniques, suggesting that both methods
ay be useful in further discrimination of plaque composi-
ion on IVUS. Dudek et al. (20) performed intracoronary
hermography in 23 acute coronary syndrome (ACS) pa-
ients showing that the procedure is safe and showing more
eterogeneity in the culprit segment than in the nonculprit
egment. Belardi et al. (21) investigated a new thermal
ensing catheter that is used in conjunction with temporary
nterruption of coronary for a brief duration of time (30 to
0 s). This technique appears feasible and safe in this
reliminary experience and able to detect differences in
emperature in the vessel wall.
MacNeill et al. (22) utilized optical coherence tomogra-
hy (OCT) techniques to indirectly image macrophages or
acrophage deposition in atherosclerotic plaques, using the
tandard deviation of the optical signal from OCT images
nd deriving an index of macrophage density. They made
he intriguing observation that while superficial macrophage
ensity is similar for ST-segment elevation MI and ACS,
he patterns vary significantly, with greater heterogeneity
ound in the ACS group (22).
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July 21, 2004:13A–15A ACC 2004 Annual Session HighlightsMintz et al. (23) presented an IVUS technique of
virtual histology,” using spectral analysis of back-scattered
VUS images to classify plaque composition as calcium,
brotic, fibro-fatty, or lipid core. This was the first in vivo
emonstration of this in humans in an experience of 50
atients and 68 arteries, and, intriguingly, there were
orrelations noted between virtual histology images and
igh-density lipoprotein, although no correlation existed
ith low-density lipoprotein, an interesting visual biologic
inkage.
ther interventional techniques. The initial results of the
ew percutaneous left atrial appendage transcatheter occlu-
ion (PLAATO) technique were presented by Bayard et al.
24). This intriguing technique involves the percutaneous
losure of the left atrial appendage in patients with atrial
brillation to reduce the risk of thrombus formation and
troke. The overall experience includes 103 patients whose
ge spanned the spectrum but shifted more toward older
atients. The primary outcomes in these patients indicate a
ery low incidence of neurologic outcomes with the use of
his device.
ummary. At the ACC this year, a tremendous amount of
nformation was presented. As Martin Fisher once said,
Knowledge is the process of piling up facts. Wisdom lies in
heir simplification.” The world of interventional cardiology
as moved beyond coronary artery disease and peripheral
ascular disease. We are exploring techniques of adjunctive
harmacology, myocardial salvage, and valvular disease.
urthermore, these horizons continue to expand. In many
ays, interventional cardiology is a microcosm of cardiology
s a whole. There has been a lot of overlap among the
arious different compartmentalized sessions at these meet-
ngs; this overlap is part of the larger world of cardiology
hat moves beyond the borders of the individual disciplines,
nd interventional cardiology is an integral part of this larger
orld. According to Confucius, “the essence of knowledge
s: having it—to apply it; not having it—to confess our
gnorance.” Also, as Satchel Paige says, “It’s not just what
ou don’t know that hurts you, it’s what you think you know
hat just ain’t so.”
eprint requests and correspondence: Dr. James J. Ferguson,
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